Pincus Equity Partners Lpwa... Net Worth

The estimated Net Worth of Pincus Equity Partners Lpwa... is at least $22.9 millió dollars as of 30 May 2007. Pincus Lpwa owns over 677,200 units of Sunesis Pharmaceuticals Inc stock worth over $22,897,679 and over the last 19 years Pincus sold SNSS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Pincus Lpwa SNSS stock SEC Form 4 insiders trading

Pincus has made over 3 trades of the Sunesis Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Pincus bought 677,200 units of SNSS stock worth $2,999,996 on 30 May 2007.

The largest trade Pincus's ever made was buying 805,153 units of Sunesis Pharmaceuticals Inc stock on 17 March 2006 worth over $5,000,000. On average, Pincus trades about 642,451 units every 203 days since 2005. As of 30 May 2007 Pincus still owns at least 4,304,075 units of Sunesis Pharmaceuticals Inc stock.

You can see the complete history of Pincus Lpwa stock trades at the bottom of the page.

Insiders trading at Sunesis Pharmaceuticals Inc

Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.

What does Sunesis Pharmaceuticals Inc do?

Complete history of Pincus Lpwa stock trades at Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc executives and stock owners

Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Adam Craig,
  Executive Vice President - Development, Chief Medical Officer
• Stephen Ketchum,
  Director
• David Stump,
  Independent Director
• Homer Pearce,
  Independent Director
• Nicole Onetto,
  Independent Director
• Matthew Fust,
  Independent Director
• Steve Carchedi,
  Independent Director
• H. Ward Wolff,
  Director
• Tina Gullotta,
  Principal Accounting Officer, Vice President - Finance
• Dayton Misfeldt,
  Chief Executive Officer, Principal Financial Officer, Secretary, Director
• James Young,
  Non-Executive Independent Chairman of the Board
• Eric Bjerkholt,
  EVP, CFO & Corp. Secretary
• Geoffrey M. Parker,
  Director
• Steven B Ketchum,
  Director
• Daniel N Jr Swisher,
  President and CEO
• Oncology Impact Management ...,
  
• William P. Quinn,
  See Remarks
• Judith A. Fox,
  See Remarks
• Patrick J Kerins,
  10% owner
• Ryan D Drant,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Equity Opportunities Fund, ...,
  
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Helen Susan Kim,
  Director
• Joseph I De Pinto,
  EVP, CCO
• Biopharma Partners Iii Lpal...,
  
• Equity Opportunities Fund, ...,
  
• Robert Scott Mc Dowell,
  Vice President, Research
• Edward Hurwitz,
  Director
• Dominique Semon,
  10% owner
• Biopharma Partners Iii Lpal...,
  
• Iii Eugene A Trainor,
  10% owner
• Charles M Linehan,
  10% owner
• Equity Opportunities Fund, ...,
  
• Pincus Equity Partners Lpwa...,
  
• Valerie L Pierce,
  Sr. VP, GC & Corp. Secretary
• Anthony B Evnin,
  Director
• Steven D Goldby,
  Director
• James A Wells,
  Director
• Stephen P A Fodor,
  Director
• Idec Incbiogen Idec Ma Inc ...,
  
• Pincus Equity Partners Lpwa...,
  
• Daniel C Md Adelman,
  Senior VP,Drug Discovery & Dev
• Ixmayfield Ix Management Ll...,
  
• Jonathan S Leff,
  Director
• Daryl B Winter,
  SVP,Gen Counsel/Corp Secretary
• Capital Iv, Lp Aisling Capi...,